153645-26-2

Basic information

• Product Name: (S)-N-BOC-TERT-LEUCINOL 98
• Synonyms: (S)-N-BOC-TERT-LEUCINOL 98;)-N-Boc-tert-leucinol;N-[(1S)-1-(HydroxyMethyl)-2,2-diMethylpropyl]carbaMic Acid 1,1-DiMethylethyl Ester;Boc-tert-leucinol;(S)-TERT-BUTYL (1-HYDROXY-3,3-DIMETHYLBUTAN-2-YL)CARBAMATE
• CAS NO: 153645-26-2
• Molecular Formula: C₁₁H₂₃NO₃
• Molecular Weight: 217.307
• Product Categories: Amino Acid Derivatives;Amino Alcohols;Peptide Synthesis;Amino Acids & Derivatives;Chiral Reagents
• Mol File: 153645-26-2.mol
• Article Data: 23

Chemical Properties

• Melting Point: 102-103 °C
• Boiling Point: 313.7°C at 760 mmHg
• Flash Point: 143.5°C
• Appearance: White/Crystalline Powder
• Density: 0.986g/cm³
• Vapor Pressure: 4.25E-05mmHg at 25°C
• Refractive Index: 1.455
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 12.11±0.46(Predicted)
• CAS DataBase Reference: (S)-N-BOC-TERT-LEUCINOL 98(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-N-BOC-TERT-LEUCINOL 98(153645-26-2)
• EPA Substance Registry System: (S)-N-BOC-TERT-LEUCINOL 98(153645-26-2)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 153645-26-2(Hazardous Substances Data)

Usage

Uses

N-Boc-(S)-(+)-tert-leucinol (cas# 153645-26-2) is a compound useful in organic synthesis.

InChI:InChI=1/C11H23NO3/c1-10(2,3)8(7-13)12-9(14)15-11(4,5)6/h8,13H,7H2,1-6H3,(H,12,14)/t8-/m1/s1

Upstream product

• 20859-02-3 L-tert-Leucine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 152488-38-5 (R)-1-chloro-3,3-dimethyl-2-butanol 
• 352545-44-9 (S)-t-butyl-leucinol; hydrochloride 
• 335627-99-1 tert-butyl N-[(1S)-1-formyl-2,2-dimethylpropyl]carbamate 
• 34619-03-9 tert-butyldicarbonate 
• 112245-13-3 (S)-tert-leucinol 
• 335627-81-1 (4S,5R)-4-tert-butyl-5-methoxy-2-oxazolidinone 
• 62965-35-9 N-tert-butyloxycarbonyl-L-tert-leucine 
• 335628-21-2 (4S,5R)-3-tert-butoxycarbonyl-4-tert-butyl-5-methoxy-2-oxazolidinone 
• 176504-88-4 2-tert-butoxycarbonylamino-3,3-dimethylbutyric acid methyl ester 

Downstream Products

• 229485-69-2 (S)-[-2,2-dimethyl-1-[[[(4-methylphenyl)sulfonyl]oxy]methyl]propyl]carbamic acid 1,1-dimethylethyl ester 
• 864824-95-3 C₁₇H₂₇NO₃ 
• 1073176-41-6 (S)-tert-butyl 3,3-dimethyl-2-(2-nitro-4-(trifluoromethyl)phenylamino)butan-1-yl carbonate 
• 1073176-30-3 (S)-tert-butyl(3,3-dimethyl-1-(2-nitro-4-(trifluoromethyl)phenoxy)butan-2-yl)carbamate 
• 62965-35-9 N-tert-butyloxycarbonyl-L-tert-leucine 
• 1073176-43-8 (S)-tert-butyl(1-(2-amino-4-(trifluoromethyl)phenoxy)-3,3-dimethylbutan-2-yl)carbamate 

Relevant articles and documents

A convenient synthesis of (1S)-tert-butyl-1,2-ethylenediamine

A practical four-step synthesis of (1S)-tert-butyl-1,2-ethylenediamine has been developed. The sequence proceeds in good overall yield via crystalline intermediates and provides the title compound in 99.3% ee. Copyright (C) 2000 Elsevier Science Ltd.

Isoselective ring-opening polymerization and asymmetric kinetic resolution polymerization of: Rac -lactide catalyzed by bifunctional iminophosphorane-thiourea/urea catalysts

A series of iminophosphorane-thiourea/urea bifunctional catalysts was synthesized and utilized for the isoselective ring-opening polymerization of rac-lactide. The ROPs were promoted efficiently, affording the polylactides with controlled molecular weight, narrow molecular weight distribution and well-defined end groups without undesired side reactions. The experiment data revealed that ROPs of rac-LA are a "controlled/living" process. The highest stereoselectivity (Pm) was up to 0.80 using rac-IPU-1 under mild reaction conditions. The mechanistic study indicated that stereoselective ROPs of rac-LA were mainly controlled by a chain-end control mechanism when using rac/(R,R)-IPTU-1/IPU-1 as catalysts. Additionally, the ee values of -11% at 0 °C and -17% at -40 °C were achieved at about 50% conversion using (S)-IPU-2 as a chiral catalyst. The selectivity factor (s = kL/kD) of 1.6 indicated that a clear kinetic resolution occurred and the enantiomorphic site control mechanism was involved.

N-1 BRANCHED ALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS

Imidazo[4,5-c]quinoline compounds having a substituent that is attached at the N-1 position by a branched group, single enantiomers of the compounds, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing (or inhibiting) cytokine biosynthesis in humans and animals, and in the treatment of diseases including infectious and neoplastic diseases are also disclosed.